Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.
View the full Corporate Spotlight
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.010(6.25%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.5¢ | 16.5¢ | $44.47K | 261.8K |
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41690 | 17.0¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 3167 | 2 |
| Last trade - 16.10pm 06/12/2024 (20 minute delay) ? |
|
|||||
|
Last
17.0¢ |
Change
0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 17.0¢ | 18.0¢ | 16.5¢ | 156405 | ||
| Last updated 15.08pm 06/12/2024 ? | |||||
| NUZ (ASX) Chart |
ASX News
